Ono Pharmaceutical pays $80M for regional rights to Biohaven's IgG degraders

Ono Pharmaceutical is paying Biohaven $80 million upfront, plus a $20 million milestone and a 20% profit share, to license regional rights for three IgG degraders in Japan and select Asian markets. The deal is led by BHV-1300, a phase 3 candidate for Graves' disease. Analysts at Raymond James reiterate a Strong Buy rating, calculating that the deal extends Biohaven's cash runway into 2029 to support its U.S. launch, offsetting a negative free cash flow of $512 million.

Details of the licensing agreement

• ▪Ono Pharmaceutical agreed to pay Biohaven $80 million upfront to license regional rights for three IgG degraders, including the phase 3 Graves' disease candidate BHV-1300.
• ▪The licensing agreement grants Ono Pharmaceutical rights to the three Biohaven IgG degraders in Japan, South Korea, Taiwan, and members of the Association of Southeast Asian Nations.
• ▪The licensing agreement between Ono Pharmaceutical and Biohaven includes a $20 million milestone payment expected within a year and a 20% cut of profits from sales in the licensed territories.

Profile of the licensed IgG degraders

• ▪Biohaven released data in January 2026 suggesting that a Graves' disease patient treated with BHV-1300 experienced complete suppression of disease-causing TSH receptor-stimulating antibodies.
• ▪The three licensed Biohaven assets, BHV-1300, BHV-1310, and BHV-1320, originated from the Spiegel Lab at Yale University.
• ▪Biohaven's BHV-1300 is a protein degrader designed to selectively target IgG1, 2, and 4 while sparing IgG3, and is currently being evaluated in a phase 3 trial for Graves' disease.

Impact on Biohaven's financial runway

• ▪Raymond James calculated that the licensing deal with Ono Pharmaceutical extends Biohaven's cash runway at least into 2029, supporting the company through the modeled late-2028 U.S. launch of BHV-1300.
• ▪Biohaven's extended cash runway is significant given its levered free cash flow of negative $512 million over the last twelve months, despite a strong short-term current ratio of 4.73.

Ono Pharmaceutical's immunology pipeline

• ▪Ono Pharmaceutical's immunology and inflammation pipeline includes bifunctional fusion proteins licensed from Shattuck Labs and regional rights to Vertex Pharmaceuticals' IgA nephropathy prospect povetacicept.
• ▪Ono Pharmaceutical entered the Biohaven deal to strengthen its late-stage immunology and inflammation pipeline, which Chief Operating Officer Toichi Takino described as a key focus area.

Raymond James' post-deal outlook

• ▪Raymond James reiterated a Strong Buy rating and a $30.00 price target on Biohaven Pharma shares following the announcement of the licensing agreement with Ono Pharmaceutical.
• ▪Raymond James' revenue estimates for Biohaven's BHV-1300 program remained unchanged following the announcement of the licensing deal with Ono Pharmaceutical.

Biohaven's BHV-7000 program

• ▪Raymond James previously identified Biohaven's August 2026 deal to out-license BHV-7000 to SK Biopharma as a key catalyst for reducing the company's financing overhang.
• ▪The U.S. Food and Drug Administration placed a partial clinical hold on Biohaven's BHV-7000 epilepsy clinical program, pausing new patient enrollment.

RBC Capital's outlook

• ▪RBC Capital downgraded Biohaven's stock to Sector Perform from Outperform and adjusted its price target to $19.00 from $23.00, citing the stock's approximately 100% rise since earlier in 2026.
• ▪RBC Capital acknowledged that Biohaven's Kv7 program deal enhanced Biohaven's balance sheet and provided visibility for future data readouts.